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Abstract The purpose of this study was to characterize the
recurrence dynamics in breast cancer patients after delayed
reconstruction. We hypothesized that surgical reconstruc-
tion might stimulate dormant micrometastases and reduce
time to recurrence. All mastectomy breast cancer patients
with delayed surgical reconstruction at Haukeland
University Hospital, between 1977 and 2007, n = 312,
were studied. Our control group consisted of 1341 breast
cancer patients without reconstruction. For each case, all
patients in the control group with identical T and N stages
and age ±2 years were considered. A paired control was
randomly selected from this group. 10 years after primary
surgery, 39 of the cases had relapsed, compared to 52 of the
matched controls. The reconstructed group was analyzed
for relapse dynamics after mastectomy; the first peak in
relapses was similarly timed, but smaller than for the
controls, while the second peak was similar in time and
size. Second, the relapse pattern was analyzed with
reconstruction as the starting point. A peak in recurrences
was found after 18 months, and a lower peak at the 5th–6th
year. The height of the peak correlated with the extent of
surgery and initial T and N stages. Timing of the peak was
not affected, neither was the cumulative effect. The relapse
pattern, when time origin is placed both at mastectomy and
at reconstruction, is bimodal with a peak position at the
same time points, at 2 years and at 5–6 years. The timing
of the transition from dormant micrometastases into clini-
cally detectable macrometastases might be explained by an
enhancing effect of surgery.
Keywords Breast cancer  Surgery  Breast
reconstruction  Recurrence dynamics  Tumor dormancy 
Multivariate regression
Introduction
The major cause of breast cancer mortality is metastatic
disease, and the prevention of metastatic spread and growth
is the aim of primary local and systemic therapy [1]. Still,
after initial treatment with curative intent, breast cancer is
known for its potential to cause late relapse. Even tiny
tumors, undetectable by physical, biochemical, or radio-
logical examination, can shed malignant cells into the
circulation and eventually cause recurrences up to 20 years
after the primary surgery [1]. The current view of breast
cancer as a systemic disease at the time of diagnosis was
introduced by Fisher in the late 1960s [2]. The concept of
tumor dormancy has been proposed [3–6] as an explanation
of the latency of metastatic disease, and the past and cur-
rent research is beginning to unravel the mechanisms of
maintenance as well as disruption of dormancy [7]. Early
micrometastatic foci can be restricted in growth over
periods of time by inability to recruit blood vessels [8], by
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immune surveillance [9, 10], by cell cycle arrest [11], or by
tumor–microenvironment (TME) interactions [12].
Signs of stimulation of micrometastases after surgical
intervention have been observed in experimental and epi-
demiological studies and evaluated in mathematical models
[13–15]. Furthermore, clinical investigations support an
enhancing effect on the growth of metastases after surgical
primary tumor removal [16, 17]. Tissue trauma and sub-
sequent wound healing have been shown to cause both
local and systemic growth signaling cascades, and might
thereby possibly alter the dormant state of occult
micrometastases [18, 19]. In a previous study, our findings
indicated the presence of synchronized tumor growth in
metastatic breast cancer [20]. In some reports on human
cancers such as primary breast cancer [21], ovarian [22],
colorectal [23], lymphoma [24], and others, tissue trauma
has been associated with tumor progression. It was pro-
posed that the primary surgery by itself can represent a
stimulating event responsible for the peak in the incidence
of metastatic disease observed around 2 years postopera-
tively independent of tumor stage [25–27]. In light of these
findings, questions have been raised regarding the safety of
delayed reconstructive surgery. Both increased and reduced
risk of recurrence was reported after delayed breast
reconstruction [28, 29]. The aim of the present study was to
characterize the recurrence dynamics in breast cancer
patients that underwent delayed reconstructive surgery. We
hypothesized that delayed reconstructive surgery might
stimulate preexisting, occult dormant micrometastases and
alter the recurrence dynamics.
Patients and methods
Study population
The study population for this retrospective analysis consists
of all mastectomy breast cancer patients who underwent
delayed reconstructive surgery at Haukeland University
Hospital, Bergen, Norway, and had their primary treatment
between 1977 and 2007. The respective reconstructive
procedures were implant surgery, implants combined with
flaps, deep inferior epigastric perforator (DIEP) flaps, and
transverse rectus abdominis myocutaneous (TRAM) flaps.
Distinction was not made between single- and multistage
surgery. Altogether, 312 patients were included after
exclusion of patients for whom both tumor size and nodal
status were not known as well as patients with secondary,
nonbreast cancers and DCIS (ductal carcinoma in situ)
(Fig. 1). The hospital covers a population of 600,000, and
in this period, all late reconstructive surgical interventions
following breast cancer in the region were performed here.
Each patient’s record was studied to validate diagnosis,
patient and tumor characteristics, adjuvant therapy, time
and type of reconstructive surgery, time of first recurrence,
and recurrent site.
Control group
We received a control population from the Norwegian
Cancer Registry comprising 1341 patients with breast
cancer surgery in the same time period that had not
undergone reconstructive surgery. Reporting breast cancer
treatment to this registry is mandatory for all physicians in
Norway, and the latest published evaluation from 2007
showed a 99 % completeness of data [30]. For data quality
purposes, patient’s records were studied for validation of
diagnosis, patient and tumor characteristics, adjuvant
therapy, reconstructive surgery (excluded from the control
group), time of first recurrence, and recurrent site in the
same way as was done with the cases. Among the 1341
patients, a total of 473 patients were excluded (see Fig. 1
for details) leaving 868 patients, whose characteristics are
shown in Table 1, which hereafter will be labeled ‘‘control
group.’’
Matching
For each patient in the reconstruction group, all patients in
the control group with identical T and N stages,
age ± 2 years, and follow-up without recurrence equal to
or longer than the time to reconstruction of the respective
matched reconstructed patient were considered. In this
initial step, each case could have a number of candidate
controls of 0-X. A reference day was calculated for each of
the controls in these groups representing time from primary
surgery for the control plus time from primary surgery until
reconstruction for the matched case. Therefore, time from
primary surgery until reconstruction/reference day could
by calculated for cases and controls, respectively. A paired
control was randomly selected from this group. If this
group was empty, increased age interval up to 5 years was
allowed as a first step, and in a few cases when the age
difference was considered clinically relevant (e.g., pre- vs
postmenopausal), patients with similar, but not identical T
classification (e.g., T2 instead of T1) within the right age
interval were considered. This group of 312 patients, whose
characteristics are shown in Table 1, will be hereafter
labeled ‘‘matched control group.’’
Follow-up
Time to recurrence (TTR) was recorded as the time from
primary surgery to recurrence. The endpoint of primary
interest was the first evidence of recurrence: survival times
were calculated as the time elapsed since primary surgery
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Breast reconstruction cohort n= 445 Control population from the Norwegian 
cancer registry n= 1341.
Matched control group
(no reconstruction) n= 312 
Study population (reconstruction) 
n= 312
Excluded n= 132
DCIS/LCIS n= 72
BCT n= 53
No cancer n= 1
Occurrence of other malignancies n= 4
Recurrence before reconstruction n= 3
Missing information n=1
Excluded n= 473
DCIS/LCIS n= 37
Reconstructed n= 179
BCT n= 196
Missing information n= 61
Control group = 868
Matching on T, N, age,  follow up free from 
recurrence1
Fig. 1 Inclusion and exclusion
criteria employed to achieve
case, control, and matched
control populations. DCIS
ductal carcinoma in situ, LCIS
lobular carcinoma in situ, BCT
breast-conserving therapy. 1
Recurrence-free follow-up time
equal to or longer than the time
to reconstruction of the
respective matched
reconstructed patient
Table 1 Patient, tumor, and treatment characteristics
Reconstruction
group n = 312 (%)
Control group
n = 868 (%)
Matched control
n = 312 (%)
Year of primary diagnosis
1977–1989 15 (4.8) 57 (6.6) 25 (8.0)
1990–1999 99 (31.7) 298 (34.3) 109 (34.9)
2000–2009 198 (63.5) 513 (59.1) 178 (57.1)
Median age at diagnosis 48.0 50.0 49.0
Mean age at diagnosis 48.1 50.7 48.7
Age\50 171 (54.8) 397 (45.7) 171 (54.8)
Age C50 141 (45.2) 471 (54.3) 141 (45.2)
Tumor size
T1 190 (60.9) 379 (43.7) 192 (61.5)
T2 91 (29.2) 332 (38.2) 94 (30.1)
T3 22 (7.1) 87 (10.0) 21 (6.7)
T4 2 (0.6) 43 (5.0) 2 (0.6)
Missing 7 (2.2) 27 (3.1) 3 (0.9)
Nodes
Negative 212 (67.9) 428 (49.3) 210 (67.3)
Positive 100 (32.1) 421 (48.5) 102 (32.7)
Missing 19 (2.2)
ER status
Negative 61 (19.6) 190 (21.9) 60 (19.2)
Positive 218 (69.9) 544 (62.7) 216 (69.2)
Missing 33 (10.6) 134 (15.4) 36 (11.5)
Adjuvant endocrine treatment
No 117 (37.5) 238 (27.4) 115 (36.9)
Yes 136 (43.6) 379 (43.7) 132 (42.3)
Missing 59 (18.9) 251 (28.9) 65 (20.8)
Adjuvant chemotherapy
No 144 (46.2) 327 (37.7) 136 (43.6)
Yes 143 (45.8) 305 (35.2) 125 (40.1)
Missing 25 (8.0) 235 (27.1) 51 (16.3)
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to recurrence or to the last documented follow-up with no
evidence of disease. Both locoregional recurrence and
distant metastasis were defined as the events of interest,
whereas all new primary tumors, including contralateral
breast cancers, were considered competing events, thus for
these patients survival times were censored at the time of
their occurrence. Adjuvant local and/or systemic treatment
was given according to national guidelines at the given
time period and was not affected by delayed breast
reconstruction. Follow-up after curative breast cancer
treatment in Norway does not include radiologic evaluation
or blood samples other than upon clinical suspicion of
distant metastases. Thus, diagnosis of relapse is most
commonly made after patients’ experience of symptoms.
Even when adopting more meticulous follow-up regimens,
more than 85 % of recurrences are detected following
symptomatic alert and not at controls [31]. Oncological
follow-up is not influenced by reconstructive surgery.
Statistical analysis
The event dynamics were studied by estimating with the
life-table method the hazard rate for recurrence, i.e., the
conditional probability of manifesting recurrence given
that the patient is clinically free from any recurrence at the
beginning of the interval. The probability of recurrence
over time, i.e., crude cumulative incidence (CCI), was
estimated according to a proper nonparametric estimator
adjusting for the presence of competing events and com-
pared by the Gray test [32]. A discretization of the time
axis in six-month units was applied and a Kernel-like
smoothing procedure [33] was adopted. For multivariable
regression analysis, the piecewise exponential model was
used. The piecewise exponential model provides a flexible
semiparametric tool in the study of the hazard function for
survival data, in the same fashion as a Cox regression
model [34]. The log-hazard function was modeled as an
additive function of the baseline log-hazard and the
covariate effects. For estimation of the piecewise expo-
nential model, the follow-up time was split into 3-month
disjoint intervals and the event rate was assumed to be
constant within each interval. The model accounts for
reconstruction as a time-dependent covariate (i.e., switch-
ing from 0 to 1 at the time it was performed). The model
was extended to account for the new timescale induced by
reconstructive surgery, namely the time elapsed since
reconstruction to the endpoint of interest [35]. For practical
purposes, time since reconstruction assumed the value 0,
before its occurrence, as well as for the controls.
Available prognostic factors were taken into account to
adjust the multivariable regression model. These included
age at diagnosis, pathologic tumor size (T2–T4 vs. T1),
nodal status (N? vs. N0), and estrogen receptor status
(ER? vs. ER-), with time-dependent effect (by introduc-
ing Time (since primary tumor surgery) * ER interaction).
To allow for the estimation of baseline hazard, both
timescales were modeled via Natural Splines with 5 knots
(corresponding to the quantiles of event times only). For
age at diagnosis, a possible nonlinear effect was also tested.
Statistical analyses were done using R3.02 software for
Windows, with Epi package added.
Results
Of the 312 patients, 302 had reconstructive surgery within
180 months and 291 within 120 months after primary
surgery, whereas the remaining 10 had longer time to
reconstruction. Median time to reconstruction was
33 months (range: 1–362 months). Median follow-up after
reconstruction was 137 months. Within 10 years after pri-
mary surgery, 39 of the 312 reconstructed patients devel-
oped local (5), regional (6), or distant (31) relapse,
compared to 52 patients in the matched control group (local
10, regional 3, distant 39).
As a first step, the recurrence dynamics for the recon-
structed patients were analyzed with the time origin at
primary cancer surgery (Fig. 2, blue line). As expected, a
bimodal hazard rate pattern was observed, with an early
less prominent peak in comparison with the second later
one. When the recurrence dynamics were analyzed with
reconstructive surgery as the time origin, a distinct early
peak in recurrences was found around 18 months postre-
construction, followed by a second lower peak at the 5th–
6th year (Fig. 2, red line). The height of this peak was
dependent on the extent of surgery. More extensive surg-
eries like deep inferior epigastric perforator (DIEP) flaps,
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Fig. 2 Recurrence pattern for the reconstructed patients (n = 312)
with T = 0 set at reconstruction (red line) and at primary surgery
(blue line). X-axis represents time in months. Y-axis represents six-
month hazard rate
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transverse rectus abdominis myocutaneous (TRAM) flaps,
and combined implant and flap surgery as compared with
simple implant resulted in a higher peak for the former
(Fig. 3). The timing of the peak was not affected by the
extent of surgery. There was no difference in recurrence-
free survival between extensive reconstructive surgery and
simple implant surgery (Fig. 4, Gray test, p = 0.86).
Similarly, the height of the recurrence peaks, but not the
timing, was dependent on known risk factors such as nodal
involvement and T stage (Fig. 5).
The relapse pattern for the matched control group, when
the time origin was set at mastectomy, followed the
expected bimodal pattern with a first, dominant early peak
and a second less marked peak at 5 years after primary
surgery (Fig. 6), as frequently demonstrated in previous
studies. When the time origin was moved to the reference
day, the hazard rate curve appears as a simple distortion of
the previous one (figure not reported). Unlike the recon-
structed patients, no definite trait was detectable. The
recurrence incidence was slightly reduced for the recon-
structed patients in comparison with matched control
patients, although the difference was not statistically sig-
nificant (Fig. 7, Gray test, p = 0.08).
The multiple scale analysis supports the hypothesis of a
transitory significant increase of recurrence risk during the
first two years after reconstruction/reference day for
reconstructed patients in comparison with the not recon-
structed patients. In the multivariable regression model,
where all 868 patients in the control group were analyzed,
all factors that were considered confirmed their expected
prognostic impact, including the time-dependent effect of
ER status, whereas age at diagnosis did not. The hazard
ratio (HR) was higher in node-positive patients and in those
with increasing tumor size (Table 2). The multiple time-
scale model allows for understanding whether the time
effect, induced by reconstruction occurrence, may be rel-
evant for the subsequent risk of developing unfavorable
events. To better interpret the model, a graph showing the
effect of the timescale induced by reconstruction surgery is
shown in Fig. 8. The figure shows how the hazard ratio for
recurrence between reconstructed patients and control
patients (with the same clinical and pathological features
and with the same follow-up time since primary tumor
surgery) may not be considered constant during the sub-
sequent follow-up time. Although not fully significant with
a moderately wide confidence interval, it shows an
increased risk for the reconstructed patients within the first
2 years, with a peak at about 18 months after surgery and
decreasing thereafter. Of note, the recurrence dynamics
following reconstructive surgery were unaffected by the
time from primary surgery to reconstruction, both in timing
and magnitude.
Discussion
To our knowledge, this is the first study investigating the
dynamics of recurrences occurring after delayed breast
reconstruction in breast cancer patients. The main result of
our analysis is that when the time origin is set at the
reconstruction date, the hazard rate for ensuing recurrence
displays a first main peak in the 2nd year and a later minor
peak at the 5th–6th year after reconstruction (Fig. 2, red
line). The recurrence risk for the same patients, when the
time origin is placed at mastectomy, is bimodal with peak
positions at the same time points relative to mastectomy,
after 2 and 5–6 years (Fig. 2, blue line), as expected [31].
Thus, when the time origin is moved for each reconstructed
patient to the reconstruction date, the recurrence risk pat-
tern is similar to that observed following primary mastec-
tomy. Of note, time origin displacement reveals an increase
of the early peak with a concomitant decrease of the late
level of recurrence risk (Fig. 2), suggesting that recurrence
redistribution is associated with the reconstruction
maneuver which could be said to act as a wave breaker for
recurrences. These findings suggest that mastectomy and
reconstruction induce similar biological effects on sub-
clinical preexisting metastases.
The effects of primary mastectomy have been investi-
gated in both animals and humans during the past century
[36]. An unintentional effect of surgery in breast cancer
patients with clinically undetectable micrometastatic dis-
ease has been explained by a paradigm based on the con-
cepts of tumor homeostasis, tumor dormancy, and surgery-
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Fig. 3 Recurrence pattern according to surgical intervention demon-
strates an enhanced, but similarly timed, effect by increased extent of
trauma. Blue line patients receiving a unilateral implant. Red line
patients receiving more extensive surgery. X-axis represents time in
months since reconstructive surgery. Y-axis represents six-month
hazard rate. DIEP deep inferior epigastric perforator, TRAM trans-
verse rectus abdominis myocutaneous flap
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related enhancement of metastasis growth [37]. The model
assumes both cellular and micrometastatic tumor dor-
mancy, with ordered transitions between these two quies-
cent states and subsequent development of overt metastasis
and, subsequently, a transient phase of acceleration of
metastatic growth. Preclinical studies have pointed to an
angiogenic switch as a possible involved mechanism, in
which the microenvironment is altered by tissue trauma to
become proangiogenic with increased levels of VEGF and
reduced levels of angiogenesis inhibitors such as TSP-1
[8]. Others have focused on the role of surgery-induced
immunomodulation with demonstration of a stimulatory
interaction between cells of the innate immune system and
adjacent cancer cells [38]. The truth may lie in both models
as the immune and angiogenic systems have multiple
points of intersection [39]. Our findings support the con-
cept that also delayed breast reconstruction may accelerate
metastatic growth in subjects with dormant metastatic foci
similar to the effects observed after primary surgery. This
explanation is further supported by the finding that surgical
approaches with different extents result in different recur-
rence risks, although with the same time rhythm (Fig. 3).
Specifically, the more extensive reconstruction modalities
DIEP/TRAM and bilateral surgical procedures give rise to
a higher early peak in comparison with unilateral implant
surgery. This difference is limited to the recurrence risk
level, which is differently modulated within the same time
cadence, while the two types of reconstruction do not affect
long-term outcome differently (Fig. 4).
The proposed explanation assumes that the risk of
clinical appearance of metastasis is dependent on the action
of surgery-related factors on the subclinical metastatic state
of the host. This assumption is confirmed by the marked
influence of both tumor size and nodal status on the hazard
Fig. 4 The probability of
recurrence over time, i.e., Crude
Cumulative Incidence (CCI),
was estimated according to
proper nonparametric estimator
adjusting for the presence of
competing events and was
compared between groups by
the Gray test. Simple unilateral
implant (black line) and more
extensive surgery such as DIEP/
TRAM or bilateral procedures
(red line). X-axis represents
time since reconstruction in
months. There is no observable
difference between the groups
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Fig. 5 Subgroup analysis of recurrence pattern by known prognostic
factors. Increasing T and N stages are associated with an enhancing
effect on preexisting recurrence risk. Left figure demonstrates the
recurrence dynamics for node-positive (red line) and node-negative
(blue line) reconstructed patients. Right figure demonstrates the
recurrence dynamics for reconstructed patients with tumors[2 cm
(red line) and B2 cm (blue line). X-axis represents months since
reconstruction. Y-axis represents six-month hazard rate
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level (Fig. 5). At diagnosis, these two well-known prog-
nostic factors indicate the recurrence risk during the dis-
ease course. Thus, it is coherent that an additional
triggering factor, such as delayed surgical reconstruction,
may result in different outcomes when patients with dif-
ferent underlying recurrence risk are involved.
When studying the relation between outcomes of
patients undergoing delayed reconstruction in comparison
with patients undergoing mastectomy without reconstruc-
tion, crucial problems emerge. In addition to the retro-
spective nature of such studies, the reconstructed group is
characterized by a selection event not yet occurred (and
therefore unknown) at the mastectomy time and, moreover,
occurring at varying patient-related times during follow-up,
thus raising important issues in the statistical analysis. To
overcome these drawbacks, we used two different
approaches. In the first approach, which has been fre-
quently adopted in this field in spite of its intrinsic naivety
[28, 29], we performed a matched random choice of the
control patients. For each reconstructed patient, we ran-
domly identified a matched control patient with similar
initial characteristics, selecting her among the not recon-
structed patients who were disease free at the date of
reconstruction of the considered patient. This matching
modality resulted in a good balance between the two sets of
patients (Table 1) and avoided drawbacks detectable in
published reports, such as dissimilar patient characteristics
(e.g., age) [40] or dissimilar prognostic factors [28, 29]. In
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Fig. 6 Recurrence pattern for the reconstructed patients and the
matched control patients with T = 0 at primary surgery. Red line
reconstructed patients. Blue line control patients. X-axis represents
months since primary surgery. Y-axis represents six-month hazard
rate
Fig. 7 The probability of recurrence over time, i.e., Crude Cumula-
tive Incidence (CCI), was estimated according to proper nonpara-
metric estimator adjusting for the presence of competing events and
was compared between groups by the Gray test. Red line recon-
structed patients. Blue line matched control patients. Despite match-
ing by age, time of diagnosis, and T and N stage, there is a
nonsignificant trend for a more favorable prognosis in the recon-
structed patients. X-axis represents time in months since reconstruc-
tion/reference day (see m&m) for reconstructed patients and control
patients, respectively. Y-axis represents accumulated recurrence-free
survival
Table 2 Hazard ratio for recurrence according to tumor
characteristics
HR 95 % CI
ER pos versus neg (18 months) 0.30 0.19 0.47
ER pos versus neg (60 months) 1.77 0.81 3.86
T2 versus T1 1.91 1.43 2.56
T3 versus T1 2.78 1.89 4.09
T4 versus T1 3.13 1.91 5.11
N? versus N- 1.98 1.52 2.59
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addition, the recurrence dynamics of matched controls,
when time origin was set at mastectomy (Fig. 6, blue line),
was coherent with the analogous hazard rate pattern
observable in similar patients from different databases [31].
It displays a first peak significantly higher than the corre-
sponding peak of reconstructed patients (Fig. 6, red line)
revealing that, in spite of the balanced initial prognostic
factors, matched control patients display worse prognosis
than reconstructed patients. This finding is consistent with
a population-based registry study analyzing Danish women
who received reconstruction with implants only [41].
In the second approach, we addressed the analysis in the
framework of multiple timescales in multistate models [35].
The regression analysis involved all 868 control patients
and 312 reconstructed patients. It accounted for the joint
effect of prognostic factors (e.g., tumor size, nodal status,
etc.) and, most importantly, the change in the hazard rate for
recurrence resulting from specific events, such as recon-
struction, occurring at varying time points. The multiple
scale analysis provides evidence that following recon-
struction women suffer a transitory, significant increase of
recurrence risk during the first 2 years in comparison with
not reconstructed patients (Fig. 8). This finding provides
structural evidence for the enhancing effect of reconstruc-
tive surgery on subclinical metastases, which brings on the
temporary raise of clinically evident recurrences. Such
behavior is suggestive when it is considered in the light of
the above-reported model. Indeed, the whole pattern would
suggest that the early peak may be caused by an event that
has been brought forward, and in the absence of recon-
struction were to be expected at a later time. Taken together,
the two analysis approaches provide evidence that recon-
structed patients (a) suffer increased surgery-related recur-
rence rate following the usual bimodal pattern and
(b) display disease-free survival that is not worse (maybe
even better) than that of not reconstructed patients (Fig. 8).
Although not directly comparable, the recurrence pat-
tern analysis apparently diverges somewhat from a previ-
ous investigation where trauma or intervening surgical
procedures unrelated to cancer were not associated with an
increased rate of breast cancer recurrence [42]. Still, the
fact that the effect of delayed reconstruction on the
recurrence dynamics does not translate into reduced
recurrence-free or overall survival is in keeping with most
reports on the same subject [28, 29, 40, 41, 43]. The reason
underlying the similar or relatively better long-term out-
come of reconstructed patients is presently undetermined.
Patients opting for reconstruction tend to be younger and
have less comorbidity. Most studies to date have focused
on immediate reconstruction [43–45]. We are inclined to
ascribe this finding to selection bias of patients receiving
reconstruction due to factors here unaccounted for, such as
socioeconomic conditions and better general health. The
former factor is related to the finding that patients who are
of lower socioeconomic status are more likely to have a
recurrence than women of higher social class [46].
Fig. 8 Multiple timescale analysis of the hazard ratio for recurrence
between the reconstructed patients and the controls in relation to time
since reconstruction. Dotted lines represent 95 % CI. X-axis
represents months since reconstruction/reference day. Y-axis repre-
sents the ratio between the six-month hazard for recurrence between
reconstructed patients and controls
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Furthermore, current smokers or diabetic patients are not
accepted for microvascular free (DIEP) or pedicle flap
surgery (TRAM). In addition, body mass index, which is a
prognostic factor in cancer [47, 48], would not be higher
than 30 in patients offered advanced reconstruction. Most
patients undergoing DIEP or TRAM procedures have a
secondary or even tertiary surgery performed due to cos-
metic purposes or complications. Thus, the observations
are measurements of the effect from the first extensive
reconstructive surgical procedure, independent of the
duration of reconstructive surgery or the number of surgi-
cal events. Again, such subsequent procedures might rep-
resent a possible bias and the observed effects might
therefore be diluted.
In conclusion, our study indicates that reconstructive
breast cancer surgery constitutes an independent stimulat-
ing event on the growth of micrometastases leading to
accelerated relapse rates. The effect is similar to that
observed after primary breast cancer surgery. Importantly,
this does not translate into worse long-term disease-free
survival. Our results may provide indirect evidence that
immediate reconstruction would be more beneficial than
delayed as this obviates one possible growth stimulating
event. Still, randomized trials assessing this question are
not ethically or practically feasible. Further studies are
ongoing and will shed more light on tumor biological
mechanisms behind the observed phenomenon.
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